Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting

被引：8

作者：

Jung, Seung Il ^{[1
]}

Kim, Myung Soo ^{[1
]}

Jeong, Chang Wook ^{[2
]}

Kwak, Cheol ^{[2
]}

Hong, Sung Kyu ^{[3
]}

Kang, Seok Ho ^{[4
]}

Joung, Jae Young ^{[5
]}

Lee, Seung Hwan ^{[6
]}

Yun, Seok Joong ^{[7
]}

Kim, Tae-Hwan ^{[8
]}

Park, Sung Woo ^{[9
]}

Jeon, Seong Soo ^{[10
]}

Kang, Minyong ^{[10
]}

Lee, Ji Youl ^{[11
]}

Chung, Byung Ha ^{[12
]}

Hong, Jun Hyuk ^{[13
]}

Ahn, Hanjong ^{[13
]}

Kim, Choung-Soo ^{[13
]}

Kwon, Dong Deuk ^{[1
]}

机构：

[1] Chonnam Natl Univ, Dept Urol, Med Sch, Gwangju, South Korea

[2] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Urol, Coll Med, Seoul, South Korea

[3] Seoul Natl Univ, Bundang Hosp, Dept Urol, Coll Med, Seongnam, South Korea

[4] Korea Univ, Dept Urol, Coll Med, Seoul, South Korea

[5] Korea Natl Canc Ctr, Ctr Prostate Canc, Dept Urol, Goyang, South Korea

[6] Yonsei Univ Hlth Syst, Severance Hosp, Dept Urol, Seoul, South Korea

[7] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Dept Urol, Coll Med, Cheongju, South Korea

[8] Kyungpook Natl Univ, Dept Urol, Sch Med, Daegu, South Korea

[9] Pusan Natl Univ, Dept Urol, Yangsan Hosp, Yangsan, South Korea

[10] Sungkyunkwan Univ, Samsung Med Ctr, Dept Urol, Sch Med, Seoul, South Korea

[11] Catholic Univ Korea, Seoul St Mary Hosp, Dept Urol, Coll Med, Seoul, South Korea

[12] Yonsei Univ, Gangnam Severance Hosp, Dept Urol, Coll Med, Seoul, South Korea

[13] Univ Ulsan, Asan Med Ctr, Dept Urol, Coll Med, Seoul, South Korea

来源：

INVESTIGATIVE AND CLINICAL UROLOGY | 2020年 / 61卷 / 01期

关键词：

Androgen antagonists; Neoplasm metastasis; Prostate neoplasms; Treatment outcome; ANDROGEN-DEPRIVATION THERAPY; HORMONE AGONIST TREATMENT; SERUM TESTOSTERONE; CESSATION; SURVIVAL; RECOVERY; TRIALS; MEN;

D O I：

10.4111/icu.2020.61.1.19

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose: This study aimed to evaluate the clinical efficacy of enzalutamide in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients using real-world data from Korean patients. Materials and Methods: We retrospectively reviewed the medical records of 199 chemotherapy-naive patients with mCRPC at 13 tertiary centers in Korea between 2014 and 2017. All patients received enzalutamide daily and 89 patients received concurrent androgen deprivation therapy (ADT). Results: The median age of the patients was 74 years. Initial results showed that 81.5% of the patients had Gleason score >= 8 and 33.3% of the patients had European Cooperative Oncology Group Performance Status 0. The overall mortality rate was 12%. The median OS was not archieved and 76.7% of patients were alive at 30 months. Median time until PSA progression was 6 months. The overall survival rate at 2 years was significantly higher (84.6% vs. 71.7%, p=0.015) and the duration of PSA progression-free survival was significantly longer (8.0 vs. 4.6 months, p=0.008) in patients receiving concurrent ADT than in those receiving enzalutamide alone. The incidence of adverse events of grade 3 or higher was 1.7%. Multivariate Cox proportional hazard analysis indicated that ADT administered concurrently with enzalutamide significantly improved the overall survival (hazard ratio, 0.346; 95% confidence interval, 0.125-0.958). Conclusions: Enzalutamide is effective and safe for chemotherapy-naive patients with mCRPC. Furthermore, the overall survival was significantly higher in patients receiving enzalutamide and concurrent ADT than in patients receiving enzalutamide alone.

引用

页码：19 / 27

页数：9

共 23 条

[1]

Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095

[2] Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer [J].